Simulations Plus and Nvidia partner to accelerate AI-driven drug modelling
Updated
Updated · Scientific Computing World · May 7
Simulations Plus and Nvidia partner to accelerate AI-driven drug modelling
11 articles · Updated · Scientific Computing World · May 7
The California-based software company said the tie-up will add GPU-optimised simulation, AI-assisted model building and parameter fitting for pharmaceutical researchers.
It will target faster, larger-scale scientific workflows, especially in quantitative systems pharmacology and pharmacokinetics/pharmacodynamics modelling used in model-informed drug development.
The collaboration aims to combine simulation software, GPU computing and AI tools to shorten drug-development timelines and improve research efficiency across the pharma sector.
With pharma giants building private AI supercomputers, can smaller biotech innovators still compete in the drug discovery race?
AI promises to design drugs in record time, but can we trust a 'black box' with our health and safety?
As AI accelerates drug discovery, will tomorrow's scientists need to be coders first and biologists second?